Stockreport

https://seekingalpha.com/article/4749593-vaxcyte-aims-to-outshine-pfizer-with-bold-vax-31-strategy [Seeking Alpha]

Vaxcyte, Inc.  (PCVX) 
PDF VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with o [Read more]